Howell SB - Search Results

1

Analysis of MLH1 and MSH2 expression in ovarian cancer before and after platinum drug-based chemotherapy.

Samimi G, Fink D, Varki NM, Husain A, Hoskins WJ, Alberts DS, Howell SB. Samimi G, et al. Among authors: howell sb. Clin Cancer Res. 2000 Apr;6(4):1415-21. Clin Cancer Res. 2000. PMID: 10778972

2

Modulation of cisplatin resistance in human malignant melanoma cells.

McClay EF, Albright KD, Jones JA, Eastman A, Christen R, Howell SB. McClay EF, et al. Among authors: howell sb. Cancer Res. 1992 Dec 15;52(24):6790-6. Cancer Res. 1992. PMID: 1458467

3

Intraperitoneal therapy in the management of patients with ovarian cancer.

McClay EF, Howell SB. McClay EF, et al. Among authors: howell sb. Hematol Oncol Clin North Am. 1992 Aug;6(4):915-26. Hematol Oncol Clin North Am. 1992. PMID: 1500393 Review.

4

Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro.

Jekunen A, Vick J, Sanga R, Chan TC, Howell SB. Jekunen A, et al. Among authors: howell sb. Cancer Res. 1992 Jul 1;52(13):3566-71. Cancer Res. 1992. PMID: 1617625

5

Expression of the c-Ha-ras oncogene in mouse NIH 3T3 cells induces resistance to cisplatin.

Isonishi S, Hom DK, Thiebaut FB, Mann SC, Andrews PA, Basu A, Lazo JS, Eastman A, Howell SB. Isonishi S, et al. Among authors: howell sb. Cancer Res. 1991 Nov 1;51(21):5903-9. Cancer Res. 1991. PMID: 1657373

6

Modulation of cis-diamminedichloroplatinum(II) accumulation and sensitivity by forskolin and 3-isobutyl-1-methylxanthine in sensitive and resistant human ovarian carcinoma cells.

Mann SC, Andrews PA, Howell SB. Mann SC, et al. Among authors: howell sb. Int J Cancer. 1991 Jul 30;48(6):866-72. doi: 10.1002/ijc.2910480613. Int J Cancer. 1991. PMID: 1713575

7

Modulation of drug sensitivity by dipyridamole in multidrug resistant tumor cells in vitro.

Shalinsky DR, Andreeff M, Howell SB. Shalinsky DR, et al. Among authors: howell sb. Cancer Res. 1990 Dec 1;50(23):7537-43. Cancer Res. 1990. PMID: 1979245

8

Intraperitoneal cisplatin-based chemotherapy for ovarian carcinoma.

Howell SB, Kirmani S, McClay EF, Kim S, Braly P, Plaxe S. Howell SB, et al. Semin Oncol. 1991 Feb;18(1 Suppl 3):5-10. Semin Oncol. 1991. PMID: 2003227 Review.

9

A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma.

Kirmani S, Lucas WE, Kim S, Goel R, McVey L, Morris J, Howell SB. Kirmani S, et al. Among authors: howell sb. J Clin Oncol. 1991 Apr;9(4):649-57. doi: 10.1200/JCO.1991.9.4.649. J Clin Oncol. 1991. PMID: 2066761 Clinical Trial.

10

The effect of DNA polymerase inhibitors on the cytotoxicity of cisplatin in human ovarian carcinoma cells.

Katz EJ, Andrews PA, Howell SB. Katz EJ, et al. Among authors: howell sb. Cancer Commun. 1990;2(4):159-64. doi: 10.3727/095535490820874515. Cancer Commun. 1990. PMID: 2114928

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

390 results

Search Page

Filters